keyword
MENU ▼
Read by QxMD icon Read
search

Cabazitaxel

keyword
https://www.readbyqxmd.com/read/29340160/stereotactic-body-radiation-therapy-for-the-treatment-of-oligoprogression-on-androgen-receptor-targeted-therapy-in-castration-resistant-prostate-cancer
#1
Thu-Cuc Nguyen, Ravneet Bajwa, Shahla Bari, Azka Ali, William Paul Skelton, Roland-Austin Federico, Rohit Bishnoi, Justin W Wray, Robert A Zlotecki, Long H Dang, Jameel Muzaffar
Castration-resistant prostate cancer is an incurable disease. To date, six agents-abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T- have shown clinical efficacy in phase III clinical trials, leading to their FDA approval. Patients are typically sequenced through most or all of these agents, and then eventually succumb to their disease. Development of new treatments remains an unmet need. We report a case of a patient who progressed on enzalutamide with a single enlarging metastatic lesion, was treated with ablative stereotactic body radiation therapy while maintaining the same systemic treatment, who then had durable complete remission...
January 2018: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/29326358/targeted-alpha-therapy-of-mcrpc-with-225actinium-psma-617-swimmer-plot-analysis-suggests-efficacy-regarding-duration-of-tumor-control
#2
Clemens Kratochwil, Frank Bruchertseifer, Hendrik Rathke, Markus Hohenfellner, Frederik L Giesel, Uwe Haberkorn, Alfred Morgenstern
The aim of this evaluation is to identify first indicators regarding the efficacy of 225Ac-PSMA-617 therapy in a retrospectively analyzed group of patients. Methods: Forty patients with metastatic castration-resistant prostate cancer were selected for treatment with 3 cycles of 100 kBq/kgBW 225Ac-PSMA-617 in 2 months intervals. Prostate-specific antigen (PSA) and blood cell count were measured every 4 weeks. Prostate-specific membrane antigen (PSMA)-PET/CT or PSMA-SPECT/CT were used for baseline staging and imaging follow-up at month six...
January 11, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29305637/psa-response-to-cabazitaxel-is-associated-with-improved-progression-free-survival-in-metastatic-castration-resistant-prostate-cancer-the-non-interventional-qolitime-study
#3
Peter Hammerer, Salah-Eddin Al-Batran, Christine Windemuth-Kieselbach, Martin Keller, Ralf-Dieter Hofheinz
PURPOSE: To evaluate the association between prostate-specific antigen (PSA) response and progression-free and overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel. METHODS: Men with mCRPC receiving cabazitaxel (25 mg/m2, every 3 weeks) plus oral prednis(ol)one (10 mg/day) were enrolled in the non-interventional, prospective QoLiTime study. Main outcome measures were progression-free survival and overall survival, in all patients and in those who showed a ≥ 50 or a ≥ 30% decrease in PSA relative to baseline after four cycles of cabazitaxel, as well as quality-of-life parameters...
January 5, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29298991/current-approaches-to-incorporation-of-radium-223-in-clinical-practice
#4
REVIEW
Chris Parker, Axel Heidenreich, Sten Nilsson, Neal Shore
BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide and abiraterone), and targeted alpha therapy (e.g., radium-223 dichloride (radium-223)). Although treatment guidelines have been updated to reflect the availability of new agents, it is not easy to apply them in daily clinical practice because recommendations vary depending on patient comorbidities and disease characteristics...
January 3, 2018: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29290963/prognostic-factors-in-men-with-metastatic-castration-resistant-prostate-cancer-treated-with-cabazitaxel
#5
Bodine P S Belderbos, Ronald de Wit, Esther Oomen-de Hoop, Annemieke Nieuweboer, Paul Hamberg, Robbert J van Alphen, André Bergman, Nelly van der Meer, Sander Bins, Ron H J Mathijssen, Robert J van Soest
Background: Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel. Results: 224 mCRPC patients were included in the current analysis. In multivariable analysis, WHO performance status, baseline hemoglobin, alkaline phosphatase and albumin were all significantly associated with OS...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29285775/systemic-immune-inflammation-index-predicts-the-combined-clinical-outcome-after-sequential-therapy-with-abiraterone-and-docetaxel-for-metastatic-castration-resistant-prostate-cancer-patients
#6
Liancheng Fan, Rui Wang, Chenfei Chi, Wen Cai, Yong Zhang, Hongyang Qian, Xiaoguang Shao, Yanqing Wang, Fan Xu, Jiahua Pan, Yinjie Zhu, Xun Shangguan, Lixin Zhou, Baijun Dong, Wei Xue
OBJECTIVE: To compare the antitumor effect of abiraterone (AA) followed by docetaxel-prednisone (DP) or vice versa in metastatic castration-resistant prostate cancer (mCRPC) patients, and explored factors that might predict combined PSA-PFS, combined rPFS and OS. PATIENTS AND METHODS: We retrospectively analyzed mCRPC patients treated with sequential therapy using DP followed by AA or vice versa. Patients who had received enzalutamide or cabazitaxel were excluded...
December 29, 2017: Prostate
https://www.readbyqxmd.com/read/29285668/cabagast-multicentre-phase-ii-study-with-cabazitaxel-in-previously-treated-patients-with-advanced-or-metastatic-adenocarcinoma-of-the-esophagogastric-junction-and-stomach
#7
Harald Schmalenberg, Salah-Eddin Al-Batran, Claudia Pauligk, Thomas Zander, Alexander Reichart, Udo Lindig, Mathias Kleiß, Lothar Müller, Claus Bolling, Thomas Seufferlein, Peter Reichardt, Frank Kullmann, Henning Eschenburg, Alexander Schmittel, Matthias Egger, Andreas Block, Thorsten Oliver Goetze
INTRODUCTION: This is a single-arm study (NCT01956149) to determine the prolonged (≥ 4 months) disease control rate with cabazitaxel administered in second-(or later) setting for patients with advanced or metastatic adenocarcinoma of the esophagogastric junction (EGJ) and stomach. METHODS: 65 patients with advanced EGJ and stomach cancer were treated with 20 mg/m2 cabazitaxel every 3 weeks for a maximum of six cycles. The main objective of the study is a prolonged disease control rate (pDCR: CR, PR or SD lasting at least 4 months)...
December 28, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29282008/pricing-appraisal-of-anti-cancer-drugs-in-the-south-east-asian-western-pacific-and-east-mediterranean-region
#8
Shahrzad Salmasi, Kah Seng Lee, Long Chiau Ming, Chin Fen Neoh, Mahmoud E Elrggal, Zaheer-Ud- Din Babar, Tahir Mehmood Khan, Muhammad Abdul Hadi
BACKGROUND: Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higher prices of anti-cancer drugs, presents a significant burden on patients and healthcare systems. The aim of the present study was to survey and compare retail prices of anti-cancer drugs between high, middle and low income countries in the South-East Asia, Western Pacific and Eastern Mediterranean regions. METHODS: Cross-sectional survey design was used for the present study...
December 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29276148/testosterone-diminishes-cabazitaxel-efficacy-and-intratumoral-accumulation-in-a-prostate-cancer-xenograft-model
#9
Lisanne Mout, Ronald de Wit, Debra Stuurman, Esther Verhoef, Ron Mathijssen, Corrina de Ridder, Martijn Lolkema, Wytske van Weerden
Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy (ADT) is the mainstay of (metastatic) prostate cancer therapy. Ultimately, the AR pathway will be re-activated despite castrate levels of circulating androgens. Thereby, maintaining its role even in castration resistant prostate cancer (CRPC). The recent STAMPEDE and CHAARTED trials showed that docetaxel in combination with ADT increased survival in hormone sensitive prostate cancer patients, suggesting cross-talk between AR signaling and chemotherapy efficacy...
December 20, 2017: EBioMedicine
https://www.readbyqxmd.com/read/29275145/taxane-based-combination-therapies-for-metastatic-prostate-cancer
#10
REVIEW
Paul G Corn, Neeraj Agarwal, John Charles Araujo, Guru Sonpavde
CONTEXT: Multiple single-agent therapies improving survival are approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including two chemotherapies, two androgen-signaling axis-targeting agents, an immunotherapeutic vaccine, and a radiopharmaceutical. Combination therapy can target multiple oncogenic pathways simultaneously, while potentially curbing the development of treatment resistance. OBJECTIVE: To provide a succinct overview of taxane-based combination therapies currently being evaluated for the treatment of metastatic prostate cancer...
December 20, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29247284/third-line-treatment-and-177lu-psma-radioligand-therapy-of-metastatic-castration-resistant-prostate-cancer-a-systematic-review
#11
REVIEW
Finn Edler von Eyben, Giandomenico Roviello, Timo Kiljunen, Christian Uprimny, Irene Virgolini, Kalevi Kairemo, Timo Joensuu
AIMS: There is a controversy as to the relative efficacy of 177Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether 177Lu-PSMA RLT and third-line treatment have similar effects and adverse effects (PROSPERO ID CRD42017067743). METHODS: The review followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines...
December 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29234258/toxicity-adverse-events-and-quality-of-life-associated-with-the-treatment-of-metastatic-castration-resistant-prostate-cancer
#12
REVIEW
Senol Tonyali, Hakan Bahadir Haberal, Emrullah Sogutdelen
Objectives: Among males, prostate cancer (PCa) is the most common cancer in Europe and the second most common cancer worldwide, especially in those aged > 70 years. With the advent of novel alternative treatments, survival in patients with advanced PCa has increased. PCa is now considered a chronic disease. Survival is an important endpoint in advanced PCa, as is quality of life (QoL). The effects of the disease and its treatment on patient health-related QoL must be taken into account when selecting the most appropriate treatment options...
November 2017: Current Urology
https://www.readbyqxmd.com/read/29231199/prostate-cancer-enzalutamide-cabazitaxel-interactions
#13
Rebecca Kelsey
No abstract text is available yet for this article.
December 12, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29224823/results-of-a-phase-ii-randomized-controlled-clinical-trial-comparing-efficacy-of-cabazitaxel-versus-docetaxel-as-second-line-or-above-therapy-in-recurrent-head-and-neck-cancer
#14
Amit Joshi, Vijay Patil, Vanita Noronha, Sachin Dhumal, Nikhil Pande, Arun Chandrasekharan, Siddharth Turkar, Hollis DSouza, Sameer Shrirangwar, Abhishek Mahajan, Supreeta Arya, Shashikant Juvekar, Atanu BhattaCharjee, Kumar Prabhash
BACKGROUND: Cabazitaxel has shown activity in squamous cancer cell lines and in taxane resistant cell lines. Hence we planned a phase 2 study to evaluate the efficacy of cabazitaxel against Docetaxel in recurrent head and neck cancer, post first line treatment. METHODS: This was a phase 2, investigator initiated, randomized controlled trial of Docetaxel (75 mg/m2) versus Cabazitaxel (20 mg/m2), in patients with head and neck cancer with ECOG performance status 0-2 who have been exposed to at least one line of chemotherapy, involving a sample size of 92 (46 per group)(CTRI/2015/06/005848)...
December 2017: Oral Oncology
https://www.readbyqxmd.com/read/29191639/population-based-analysis-of-treatment-toxicity-among-men-with-castration-resistant-prostate-cancer-a-phase-iv-study
#15
Christopher J D Wallis, Raj Satkunasivam, Refik Saskin, Symron Bansal, Girish S Kulkarni, Urban Emmenegger, Robert K Nam
OBJECTIVE: To assess the toxicity and effectiveness of contemporary metastatic castrate-resistant prostate cancer (mCRPC) treatments at a population-level, among all patients in Ontario particularly treated with newer agents including abiraterone, enzalutamide, docetaxel and cabazitaxel. METHODS: We performed a population-based, retrospective cohort study of 2439 men aged ≥65 years treated for mCRPC with abiraterone, enzalutamide, docetaxel, or cabazitaxel from 2003-2015 in Ontario, Canada...
November 27, 2017: Urology
https://www.readbyqxmd.com/read/29152111/reactive-oxygen-species-induction-by-cabazitaxel-through-inhibiting-sestrin-3-in-castration-resistant-prostate-cancer
#16
Takeo Kosaka, Hiroshi Hongo, Yasumasa Miyazaki, Koshiro Nishimoto, Akira Miyajima, Mototsugu Oya
Reactive oxygen species (ROS) production induced by taxanes in cancer cells may influence the taxane-induced cell death or the drug resistance. We investigated the correlation between the cytotoxic effect of taxanes and ROS production in human castration-resistant prostate cancer (CRPC) cell lines. Three human prostate cancer cell lines were treated with increasing concentrations of docetaxel or cabazitaxel in vitro. Cabazitaxel showed significantly higher cytotoxic efficacy than docetaxel in human CRPC cells, accompanied by elevated ROS production detected by FACS analysis...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29150561/influence-of-enzalutamide-on-cabazitaxel-pharmacokinetics-a-drug-drug-interaction-study-in-metastatic-castration-resistant-prostate-cancer-mcrpc-patients
#17
Bodine P S Belderbos, Sander Bins, Roelof W F van Leeuwen, Esther Oomen-de Hoop, Nelly van der Meer, Peter de Bruijn, Paul Hamberg, Esther N M Overkleeft, Wendy M van der Deure, Martijn Lolkema, Ronald de Wit, Ron H J Mathijssen
PURPOSE: In ongoing clinical research on metastatic castration-resistant prostate cancer (mCRPC) treatment, the potential enhanced efficacy of the combination of taxanes with AR-targeted agents, i.e. enzalutamide and abiraterone, is currently being explored. Since enzalutamide induces the CYP3A4 enzyme and taxanes are metabolized by this enzyme, a potential drug-drug interaction needs to be investigated. DESIGN: Therefore, we performed a pharmacokinetic cross-over study in mCRPC patients who were scheduled for treatment with cabazitaxel Q3W (25 mg/m(2))...
November 17, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29134562/seom-clinical-guidelines-for-the-treatment-of-metastatic-prostate-cancer-2017
#18
J Cassinello, J Á Arranz, J M Piulats, A Sánchez, B Pérez-Valderrama, B Mellado, M Á Climent, D Olmos, J Carles, M Lázaro
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29133120/enhanced-oral-absorption-and-anticancer-efficacy-of-cabazitaxel-by-overcoming-intestinal-mucus-and-epithelium-barriers-using-surface-polyethylene-oxide-peo-decorated-positively-charged-polymer-lipid-hybrid-nanoparticles
#19
Tianyang Ren, Qian Wang, Ying Xu, Lin Cong, Jingxin Gou, Xiaoguang Tao, Yu Zhang, Haibing He, Tian Yin, Haotian Zhang, Yan Zhang, Xing Tang
Polymer-lipid hybrid nanoparticles, PMONPs, were developed to improve the oral absorption of cabazitaxel (CTX), a semi-synthetic taxane derivative, by overcoming multiple gastrointestinal barriers. The nano-carrier is comprised of a poly(ε-caprolactone) (PCL) and chain triglyceride (MCT) hybrid core for drug loading, and a positively charged surface while slightly concealed with a polyethylene oxide (PEO) shell by insertion of poloxamer 188, with the aim of improving the intestinal mucus permeation and epithelial cell uptake...
November 10, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29129028/improved-cancer-specific-free-survival-and-overall-free-survival-in-contemporary-metastatic-prostate-cancer-patients-a-population-based-study
#20
Marco Bandini, Raisa S Pompe, Michele Marchioni, Emanuele Zaffuto, Giorgio Gandaglia, Nicola Fossati, Luca Cindolo, Francesco Montorsi, Alberto Briganti, Fred Saad, Pierre I Karakiewicz
OBJECTIVES: Over the past decade, several systemic agents as docetaxel, cabazitaxel, sipuleucel-T, abiraterone and enzalutamide have improved overall survival (OS) in metastatic prostate cancer (mPCa) patients. However, to date the OS benefit was not demonstrated in population-based analysis. METHODS: Between 2004 and 2014, 19,047 men with de novo mPCa were identified within the Surveillance Epidemiology and End Results database. Median year of diagnosis resulted in two groups: historical (2004-2008) and contemporary (2009-2014)...
November 11, 2017: International Urology and Nephrology
keyword
keyword
105580
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"